Exscientia to present at Numis T500 Conference 2018 – Linking innovative companies with investors

Exscientia, the innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is pleased to announce that its COO Mark Swindells has been selected to join an elite group of companies invited to present at the Numis T500 Conference (Tuesday 10th - Thursday 12thJuly 2018) at Numis Securities,London. Dr Swindells will be accompanied by Exscientia Chairman Alex Snow

Dr Swindells will provide an overview of the Company and the significant progress it has made over the last few years in a presentation to invited investors and discuss Exscientia’s strategies for growth on Tuesday 10thJuly. In 2017 the Company announced collaborations with GSK and Sanofi as well as a significant investment from Evotec.

Numis Venture Broking is set to host the first T500 conference, connecting its 400 top investors (T400) with its top 100 companies (T100). More information is available here: https://www.numiscorp.com/x/t500.html

About Exscientia

Exscientia is at the forefront of Artificial Intelligence (AI)-driven drug discovery and design. By fusing the power of AI with the discovery experience of seasoned drug hunters, Exscientia is the first company to automate drug design, surpassing conventional approaches. 

Exscientia’s innovative platform enables breakthrough productivity gains as well as new approaches to improve drug efficacy. Novel compounds prioritised for synthesis by its AI systems simultaneously balance potency, selectivity and pharmacokinetic criteria in order to deliver successful experimental outcomes. 

By applying a rapid design-make-test cycle, the Exscientia AI platform actively learns from the preceding experimental results and rapidly evolves compounds towards the desired candidate criteria.

Exscientia systems learn from both existing data resources and experimental data from each design cycle. The principle is similar to how a human would learn, but the AI process is far more effective at identifying and assimilating multiple subtle and complex trends to balance potency, selectivity and pharmacokinetic criteria. 

As a result, the AI-driven process is more likely to achieve the end goal and to do this more rapidly and efficiently than traditional human endeavour.

Exscientia is collaborating with several leading pharmaceutical companies. In addition to Evotec, partners include Sanofi and GSK.

Publication including Exscientia’s Chief Chemist Andy Bell, describes a potential new treatment for the common cold

Exscientia, is delighted to note that its Chief Chemist Andy Bell, who previously led a medicinal chemistry team at Imperial College, has published ground-breaking work that identifies novel molecules to treat the common cold.

The research, published in Nature Chemistry, describes work behind the design of IMP-1088, a novel and highly potent anti-viral that prevents the cold virus from making new copies of itself. By targeting a human protein (N-myristoyltransferase) rather than a cold virus protein, the emergence of drug resistance to IMP-1088 is expected to be minimised. Further research leading to human clinical trials is anticipated.
 
To learn more, see the announcement by Imperial College and the original publication.
 

Exscientia Appoints Alex Snow, Founder of Oxford Innovation Sciences and Former CEO of Lansdowne Partners, as Deputy Chairman

Exscientia, the innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is pleased to announce the appointment of Mr Alex Snow to its Board of Directors as Deputy Chairman. He brings significant strategic development and financial experience to the board.

Evotec Invests in Exscientia to advance AI-driven Drug Discovery

  • Evotec to invest € 15 M in Exscientia, A pioneer of Artificial Intelligence (“AI”) in drug discovery
  • New funds will enable Exscientia to accelerate growth
  • Expansion of existing partnership to discover novel immuno-oncology therapeutics
  • First Evotec project supported by recent € 75 M loan facility from the European Investment Bank

Hamburg, Germany, Dundee, UK: 28 September 2017
Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) and Exscientia Ltd (“Exscientia”) today announced that Evotec has made a € 15 M investment to take a minority stake in Exscientia. Through this investment, Evotec becomes the first strategic shareholder in the UK based company. Exscientia is focused on Artificial Intelligence (“AI”)-driven drug discovery and design. With more than 1800 scientists, Evotec has one of the largest and leading drug discovery platforms in the industry.